LLY Form 4: director defers pay into 14.525 stock units
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Eli Lilly (LLY) director reported acquiring 14.525 shares of common stock on 10/20/2025 at $808.96 per share. The award was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares following the director’s separation from service. After the transaction, beneficial ownership was 55,151.946 shares directly and 758 shares indirectly by trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Alvarez Ralph
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 14.525 | $808.96 | $12K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 55,151.946 shares (Direct);
Common Stock — 758 shares (Indirect, By Trust)
Footnotes (1)
- At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
FAQ
Who reported the transaction for LLY and what is their role?
A director of Eli Lilly reported the transaction on a Form 4.
What did the LLY director acquire and at what price?
The director acquired 14.525 shares at $808.96 per share.
When did the reported LLY transaction occur?
The earliest transaction date was 10/20/2025.
What is the director’s beneficial ownership after the trade?
Beneficial ownership totaled 55,151.946 shares directly and 758 shares indirectly by trust.
Does the filing mention indirect ownership details?
Yes. It lists 758 shares held indirectly by trust, with beneficial ownership disclaimed except for pecuniary interest.